|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 205/04 | (2006.01) |
| A61K 31/397 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 37/00 | (2006.01) |
| (11) | Number of the document | 2676953 |
| (13) | Kind of document | T |
| (96) | European patent application number | 13177190.9 |
| Date of filing the European patent application | 2009-12-16 | |
| (97) | Date of publication of the European application | 2013-12-25 |
| (45) | Date of publication and mention of the grant of the patent | 2017-03-22 |
| (46) | Date of publication of the claims translation | 2017-06-26 |
| (30) | Number | Date | Country code |
| 203053 P | 2008-12-18 | US |
| (72) |
Ciszewski, Lech, US
De La Cruz, Marilyn, US
Karpinski, Piotr H., US
Mutz, Michael, CH
Riegert, Christian, CH
Vogel, Caspar, CH
Sschneeberger, Ricardo, CH
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | 1-[4-[1-(4-Cikloheksil-3 -trifluormetil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilinės rūgšties hemifumarato druska, skirta panaudoti gydant limfocitų tarpininkavimo ligas |
| HEMIFUMARATE SALT OF 1-[4-[1-(4-CYCLOHEXYL-3 -TRIFLUOROMETHYL-BENZYLOXYIMINO)-ETHYL]-2-ETHYL-BENZYL]-AZETIDINE-3-CARBOXYLIC ACID FOR USE IN THE TREATMENT OF LYMPHOCYTE MEDIATED DISEASES |
| Payment date | Validity (years) | Amount | |
| 2024-11-22 | 16 | 347.00 EUR |
| 2025-12-16 |